Agentic AI personalized dietary management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial compares three approaches: standard dietary education with passive recording, AI-generated static dietary goals, and AI-based adaptive dietary management with dynamic feedback. Adults undergoing health screening are assigned to one of the three groups and followed for 12 weeks. Outcomes include dietary behavior scores and metabolic health indicators measured at baseline and study end. The aim is to determine whether an agentic AI system improves dietary choices and related health metrics compared with usual care and static AI goals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 20 years or older
* Individuals from the general population who underwent a health examination at the Seoul National University Hospital Healthcare System Gangnam Center
* Individuals who are capable of independently using a smartphone and operating study-related applications or text messaging functions
* Individuals without conditions that significantly interfere with standard dietary management, as specified in the exclusion criteria \[Section 9.2 Exclusion Criteria\]

Exclusion Criteria:

* Individuals unable to use a smartphone or study-related digital program/application, including those without a smartphone or unable to operate text messaging or application-based functions.
* End-stage renal disease or patients currently receiving dialysis
* Active cancer or currently undergoing chemotherapy or radiotherapy
* Severe heart failure, liver cirrhosis, or hepatic insufficiency accompanied by varices, bleeding, ascites, hepatic encephalopathy, or jaundice
* Malabsorption disorders such as Crohn's disease or short bowel syndrome
* Poorly controlled hyperthyroidism or hypothyroidism
* Diagnosed eating disorders or severe psychiatric disorders
* Pregnant or breastfeeding women, or women who may become pregnant during study participation.
* Individuals with recent major weight-related interventions or extreme body weight changes within the past 3 months, including:Bariatric surgery such as gastrectomy or gastric bypass surgery Newly initiated anti-obesity pharmacotherapy (e.g., semaglutide/Wegovy, tirzepatide/Mounjaro)
* Individuals considered by the investigator to have poor compliance potential or otherwise deemed unsuitable for participation in the clinical study.

Where it's running

• Seoul National University Hospital Healthcare System Gangnam Center
  Seoul, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Suyeon Choi, MD, PhD
• Email: 65390@snuh.org
• Phone: 02-2112-5639

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bone health in 12–21-year-olds starting GLP-1 weight medicines

  This study will test whether starting GLP-1 receptor agonist medicines versus lifestyle management changes bone health over 24 months in 12–21-year-olds with obesity.

  Recruiting Phase 2 University of Virginia · Charlottesville, Virginia · NCT06903923

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.